Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Merck opens first climate-neutral manufacturing facility in Ireland
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The FDA is beginning rulemaking to close the “adequate provision” loophole
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Subscribe To Our Newsletter & Stay Updated